Home » Healthcare » Pharmaceuticals » Sterile Injectables Market

Sterile Injectables Market By Drug Type (Monoclonal Antibodies, Cytokines, Insulin, Immunoglobulin, Vaccines, Peptide Hormones, Peptide Antibiotics, Blood Factors, Others); By Therapeutic Area (Cancer, Infectious Diseases, Diabetes, Cardiovascular Diseases, Neurological Diseases, Musculoskeletal Diseases, Others); By Region – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Name: Sterile Injectables Market - Demand, Size and Competitive Analysis
Creator: Credence Research Inc.
Published: 2025-09-04
License: https://www.credenceresearch.com/info/privacy-policy
Keywords: Sterile Injectables Market

Summary
Table Of Content
Request Free Sample

Market Overview

Global Sterile Injectables Market size was valued at USD 451.5 million in 2018 to USD 663.9 million in 2024 and is anticipated to reach USD 1,122.2 million by 2032, at a CAGR of 6.81% during the forecast period.

REPORT ATTRIBUTE	DETAILS
Historical Period	2020-2023
Base Year	2024
Forecast Period	2025-2032
Sterile Injectables Market Size 2024	USD 663.9 Million
Sterile Injectables Market, CAGR	6.81%
Sterile Injectables Market Size 2032	USD 1,122.2 Million

The Global Sterile Injectables Market is shaped by the strong presence of leading players such as Pfizer, Amgen, Sanofi, Johnson & Johnson, AstraZeneca, Eli Lilly, Merck, Baxter, and Mylan, each leveraging extensive biologics pipelines, oncology portfolios, and global distribution networks to strengthen competitiveness. These companies actively invest in R&D, biosimilar development, and strategic partnerships to expand market reach and improve affordability. Among regions, North America led the market in 2024 with a 33% share, supported by advanced healthcare infrastructure, favorable reimbursement systems, and rapid adoption of biologics and biosimilars. This dominance reflects the region’s strong clinical demand and innovation leadership.

Access crucial information at unmatched prices!

Request your sample report today & start making informed decisions powered by Credence Research Inc.!

Download Sample

Market Insights

The Global Sterile Injectables Market grew from USD 451.5 million in 2018 to USD 663.9 million in 2024, projected to reach USD 1,122.2 million by 2032.
Monoclonal antibodies led with 36% share in 2024, supported by oncology and autoimmune therapies, while vaccines (14%) and cytokines (12%) followed as strong growth drivers.
By therapeutic area, cancer dominated with 38% share, followed by infectious diseases (21%) and diabetes (12%), highlighting the critical role of biologics and biosimilars.
North America held 33% share in 2024, followed by Europe (28%) and Asia Pacific (23%), reflecting strong healthcare infrastructure and rising biologics adoption across regions.
Leading companies including Pfizer, Amgen, Sanofi, Johnson & Johnson, AstraZeneca, Eli Lilly, Merck, Baxter, and Mylan continue to drive innovation, biosimilar development, and competitive expansion.

Market Segment Insights

By Drug Type

In the Global Sterile Injectables Market, monoclonal antibodies lead with 36% share in 2024, driven by oncology and autoimmune treatments alongside strong biologics pipelines. Vaccines hold 14% share, supported by global immunization efforts and mRNA advancements. Cytokines represent 12%, while insulin accounts for 10% due to the diabetes burden. Immunoglobulin secures 9% share with demand in immunodeficiency therapies. Peptide hormones and peptide antibiotics capture 6% and 5% respectively, addressing endocrine and antimicrobial needs. Blood factors account for 4%, sustained by hemophilia treatments, while other injectables contribute 4% from anesthesia and diagnostic use.

For instance, Pfizer and BioNTech’s Comirnaty, the first mRNA COVID-19 vaccine to gain full FDA approval in 2021, had billions of doses administered globally, underscoring the vital role of sterile injectable vaccines in public health.

By Therapeutic Area

Cancer dominates with 38% share in 2024, fueled by high biologics adoption and targeted oncology therapies. Infectious diseases follow with 21%, benefiting from vaccine uptake and pandemic preparedness. Diabetes holds 12%, driven by insulin and GLP-1 analogs, while cardiovascular diseases capture 10% through anticoagulation and biologics. Neurological diseases account for 7%, musculoskeletal disorders 6%, and other conditions 6%, covering ophthalmology, dermatology, and gastrointestinal applications. Strong prevalence of chronic illnesses and rising biologics approvals reinforce growth across all therapeutic segments.

For instance, Merck’s immunotherapy drug Keytruda generated over $25 billion in revenue in 2023, making it one of the world’s top-selling oncology biologics.

Market Overview

Key Growth Drivers

Rising Prevalence of Chronic Diseases

The growing incidence of chronic conditions such as cancer, diabetes, and cardiovascular disorders fuels strong demand for sterile injectables. These therapies deliver rapid and targeted treatment, making them essential in critical care. Oncology dominates demand, supported by biologics like monoclonal antibodies. Increasing lifestyle-related diseases globally and a rising aging population further boost the need for injectable biologics and biosimilars. This trend positions sterile injectables as a vital treatment option across multiple therapeutic areas, ensuring sustained long-term market expansion.

For instance, Amgen’s Repatha® (evolocumab), an injectable biologic for lowering LDL cholesterol in cardiovascular patients, has been widely adopted, with over 1 million patients treated worldwide by 2021, reflecting the rising importance of sterile injectables in cardiovascular care.

Expanding Biologics and Biosimilars Pipeline

The global pipeline of biologics and biosimilars continues to expand, driving adoption of sterile injectables. Biopharmaceutical companies increasingly prioritize injectable formats for new drug launches, particularly in oncology, immunology, and infectious diseases. Patent expirations of blockbuster biologics create opportunities for biosimilars, making therapies more affordable and accessible. Regulatory approvals worldwide encourage rapid commercialization. As research shifts toward personalized medicine, injectable biologics remain the preferred choice for targeted therapies. This expanding portfolio strengthens sterile injectables’ market position across advanced and emerging economies.

For instance, in June 2025, Sandoz launched Wyost® and Jubbonti®, the first interchangeable biosimilars for Amgen’s Xgeva® and Prolia® (denosumab) in the U.S., enhancing access to lower-cost osteoporosis and oncology therapies.

Government and Institutional Support

Government healthcare initiatives and institutional support programs play a critical role in the adoption of sterile injectables. National immunization drives, pandemic preparedness policies, and funding for biologics infrastructure accelerate demand. Public-private collaborations foster innovation and expand access to injectable therapies in low- and middle-income countries. Favorable reimbursement frameworks in developed markets further enhance adoption. Increased investment in cold-chain infrastructure and hospital supply networks also ensures reliable distribution. This strong policy backing reinforces sterile injectables’ position as a frontline treatment modality.

Key Trends & Opportunities

Shift Toward Targeted and Personalized Therapies

Personalized medicine is reshaping the sterile injectables market, with biologics and biosimilars tailored to individual patient needs. Growth in precision oncology, immunotherapies, and advanced neurological treatments underscores this trend. Pharmaceutical companies are focusing on developing injectable therapies with higher efficacy and fewer side effects. The rising use of biomarkers and genetic profiling supports adoption. This shift creates opportunities for drug developers to expand their product portfolios while offering patients improved outcomes, making personalized sterile injectables a major opportunity segment.

For instance, Bristol Myers Squibb’s Opdivo (nivolumab), a sterile injectable immunotherapy, is prescribed based on PD-L1 biomarker testing to treat cancers such as non-small cell lung cancer, enabling greater treatment precision.

Growth of Contract Manufacturing and Outsourcing

Contract manufacturing organizations (CMOs) and outsourcing partnerships are gaining traction as companies seek cost-efficient sterile injectable production. Rising complexity of biologics manufacturing encourages outsourcing to specialized providers with advanced capabilities. CMOs support scalability, compliance, and global distribution, which are critical for meeting surging demand. Emerging markets, especially in Asia-Pacific, present opportunities for low-cost manufacturing hubs. Strategic collaborations also help biopharma firms reduce capital expenditure and speed up product launches. This trend positions outsourcing as a long-term growth enabler for the market.

For instance, Lonza Group, a Swiss-based CMO, has expanded its capabilities in cell and gene therapy production to support biopharma firms in scaling advanced therapies efficiently.

Key Challenges

High Production and Development Costs

Sterile injectable manufacturing requires sophisticated infrastructure, strict compliance, and advanced aseptic processes, leading to high production costs. Biopharmaceutical firms face significant upfront investments in facilities, quality systems, and skilled labor. Developing biologics and biosimilars adds additional R&D expenses. These costs increase financial risk, especially for smaller players, and limit affordability in low-income markets. The challenge of balancing safety, efficacy, and cost-efficiency remains critical. Manufacturers must adopt process innovations and partnerships to mitigate expenses while maintaining high quality standards.

Supply Chain and Cold-Chain Constraints

Sterile injectables require stringent handling, with cold-chain infrastructure vital for biologics and vaccines. Disruptions in global supply chains, as seen during the COVID-19 pandemic, exposed vulnerabilities in distribution networks. Many regions still lack adequate storage and logistics capabilities, limiting access to essential injectables. Maintaining temperature integrity during transport is a major challenge, especially in emerging markets. Infrastructure gaps and high logistical costs restrict equitable access. Strengthening global supply networks and investing in advanced cold-chain solutions remain essential to address these hurdles.

Regulatory and Safety Compliance Barriers

The sterile injectables market faces complex and evolving regulatory requirements that demand strict compliance. Manufacturers must adhere to Good Manufacturing Practices (GMP), sterility assurance protocols, and continuous quality monitoring. Meeting these requirements increases operational complexity and costs. Regulatory delays in approvals often slow time-to-market for new drugs. Additionally, product recalls or contamination issues can damage brand reputation and patient safety. Navigating diverse international standards poses further challenges for global players. Ensuring consistent compliance while accelerating innovation remains a pressing concern.

Regional Analysis

North America

North America leads the global sterile injectables market, accounting for 33% share in 2024 with revenues of USD 218.37 billion. Strong healthcare infrastructure, high biologics adoption, and advanced research pipelines sustain regional dominance. The U.S. drives most demand, supported by favorable reimbursement systems and rapid uptake of biosimilars. A robust presence of key pharmaceutical companies further strengthens growth. With a 6.4% CAGR, the market is projected to reach USD 359.11 billion by 2032, highlighting North America’s continued leadership in oncology, immunology, and chronic disease treatments.

Europe

Europe captures 28% share in 2024, valued at USD 182.58 billion. Rising demand for biologics, vaccines, and insulin injectables drives regional growth. Germany, France, and the UK serve as key contributors, supported by strong government healthcare initiatives and widespread adoption of biosimilars. Strategic collaborations with research institutions enhance innovation in sterile injectables. With a projected 6.5% CAGR, the market is set to reach USD 300.53 billion by 2032, positioning Europe as a consistent growth hub with balanced demand across oncology, diabetes, and cardiovascular therapies.

Asia Pacific

Asia Pacific holds 23% share in 2024, worth USD 157.56 billion, and is the fastest-growing region with a 7.5% CAGR. Rising chronic disease prevalence, expanding healthcare infrastructure, and increasing biosimilar penetration drive demand. China, India, and Japan lead the market, supported by government programs and rising investments in biologics manufacturing. Affordable production capabilities and a growing patient pool fuel regional expansion. By 2032, the market is forecasted to reach USD 280.55 billion, establishing Asia Pacific as a key driver of global growth in sterile injectables.

Latin America

Latin America accounts for 8% share in 2024, valued at USD 52.98 billion. Growth is supported by rising diabetes and cardiovascular cases, alongside government initiatives to expand healthcare access. Brazil dominates regional demand, followed by Argentina, due to strong hospital networks and improved biologics availability. Local partnerships and imports support market expansion across smaller economies. With a 7.0% CAGR, the market is expected to reach USD 90.90 billion by 2032, making Latin America a steadily expanding region in sterile injectables.

Middle East

The Middle East contributes 5% share in 2024, valued at USD 30.72 billion, and shows strong momentum with the highest regional CAGR of 7.9%. GCC countries and Israel drive demand through advanced healthcare systems and increased biologics adoption. Rising government spending on healthcare modernization and expansion of cold-chain facilities strengthen growth. Oncology and infectious disease treatments remain primary demand drivers. By 2032, the market is expected to reach USD 56.22 billion, positioning the Middle East as a rapidly expanding market within the global sterile injectables landscape.

Africa

Africa represents 3% share in 2024, valued at USD 21.71 billion, with growth driven by improving healthcare infrastructure and rising prevalence of infectious diseases. South Africa and Egypt serve as leading contributors, while other regions depend heavily on imports of biologics and vaccines. Limited access and high costs challenge broader adoption, yet government and NGO-led health initiatives are expanding reach. The market is projected to grow at a 6.1% CAGR, reaching USD 34.90 billion by 2032, highlighting steady but constrained progress in the region.

Market Segmentations:

By Drug Type

Monoclonal Antibodies
Cytokines
Insulin
Immunoglobulin
Vaccines
Peptide Hormones
Peptide Antibiotics
Blood Factors
Others

By Therapeutic Area

Cancer
Infectious Diseases
Diabetes
Cardiovascular Diseases
Neurological Diseases
Musculoskeletal Diseases
Others

By Region

North America

U.S.
Canada
Mexico

Europe

UK
France
Germany
Italy
Spain
Russia
Rest of Europe

Asia Pacific

China
Japan
South Korea
India
Australia
Southeast Asia
Rest of Asia Pacific

Latin America

Brazil
Argentina
Rest of Latin America

Middle East

GCC Countries
Israel
Turkey
Rest of Middle East

Africa

South Africa
Egypt
Rest of Africa

Competitive Landscape

The Global Sterile Injectables Market is highly competitive, characterized by the presence of leading multinational pharmaceutical companies alongside regional players. Key participants such as Pfizer, Amgen, Sanofi, Johnson & Johnson, AstraZeneca, Eli Lilly, Merck, Baxter, and Mylan dominate with strong portfolios in biologics, vaccines, and oncology therapies. These companies leverage extensive R&D pipelines, strategic acquisitions, and global distribution networks to maintain leadership. Patent expirations of blockbuster biologics are encouraging biosimilar development, intensifying competition and expanding access in cost-sensitive markets. Regional manufacturers, particularly in Asia-Pacific, are gaining momentum by offering affordable biosimilars and contract manufacturing services, further reshaping the competitive dynamics. Strategic collaborations with contract manufacturing organizations and technology partnerships also play a vital role in sustaining supply efficiency and innovation. The market reflects moderate concentration, with top players holding significant revenue share, while smaller firms compete in niche therapeutic areas and emerging regions, creating a dynamic and evolving competitive landscape.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key Players

Amgen Limited
AstraZeneca plc
Baxter International, Inc.
Eli Lilly and Company
Johnson & Johnson Services, Inc.
Merck & Co., Inc.
Mylan N.V.
Pfizer, Inc.
Sanofi
Nichi-Iko Pharmaceutical Co.
Other Key Players

Recent Developments

In March 2025, Eli Lilly, Merck, and Purdue University launched the Young Institute Pharmaceutical Manufacturing Consortium to advance sterile injectable manufacturing through AI, robotics, and aseptic processing innovation.
In March 2025, Mallinckrodt and Endo announced the merger of their generics and sterile injectables businesses, forming Par Health, with a planned spin-off in Q4 2025.
In May 2025, Amneal partnered with Apiject to install dedicated manufacturing lines supporting Apiject’s advanced delivery systems in the U.S., with annual production capacity scalable up to 400 million units to aid emergency and commercial readiness.
In January 2025, Akums Drugs & Pharmaceuticals initiated the development of a new facility dedicated to lyophilized and sterile dosage manufacturing, with a focus on injectables and biologics.

Report Coverage

The research report offers an in-depth analysis based on Drug Type, Therapeutic Area and Region. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

Demand for biologics and biosimilars will continue to drive sterile injectable adoption.
Oncology and immunology therapies will remain the largest contributors to injectable growth.
Vaccines and infectious disease treatments will see consistent demand from global health initiatives.
Contract manufacturing organizations will gain a stronger role in large-scale production.
Personalized and targeted therapies will expand the use of advanced injectable formulations.
Emerging markets will witness rapid growth due to healthcare infrastructure improvements.
Cold-chain logistics and supply chain investments will enhance global accessibility of injectables.
Strategic partnerships and acquisitions will remain central to competitive positioning.
Regulatory harmonization efforts will streamline biosimilar approvals and accelerate market entry.
Technological advances in delivery systems will improve patient compliance and treatment outcomes.

CHAPTER NO. 1 : GENESIS OF THE MARKET

1.1 Market Prelude – Introduction & Scope

1.2 The Big Picture – Objectives & Vision

1.3 Strategic Edge – Unique Value Proposition

1.4 Stakeholder Compass – Key Beneficiaries

CHAPTER NO. 2 : EXECUTIVE LENS

2.1 Pulse of the Industry – Market Snapshot

2.2 Growth Arc – Revenue Projections (USD Million)

2.3. Premium Insights – Based on Primary Interviews

CHAPTER NO. 3 : STERILE INJECTABLES MARKET FORCES & INDUSTRY PULSE

3.1 Foundations of Change – Market Overview

3.2 Catalysts of Expansion – Key Market Drivers

3.2.1 Momentum Boosters – Growth Triggers

3.2.2 Innovation Fuel – Disruptive Technologies

3.3 Headwinds & Crosswinds – Market Restraints

3.3.1 Regulatory Tides – Compliance Challenges

3.3.2 Economic Frictions – Inflationary Pressures

3.4 Untapped Horizons – Growth Potential & Opportunities

3.5 Strategic Navigation – Industry Frameworks

3.5.1 Market Equilibrium – Porter’s Five Forces

3.5.2 Ecosystem Dynamics – Value Chain Analysis

3.5.3 Macro Forces – PESTEL BreakdownCHAPTER NO. 4 :KEY INVESTMENT EPICENTER

4.1 Regional Goldmines – High-Growth Geographies

4.2 Product Frontiers – Lucrative Drug Type Categories

4.3 Therapeutic Area Sweet Spots – Emerging Demand Segments

CHAPTER NO. 5: REVENUE TRAJECTORY & WEALTH MAPPING

5.1 Momentum Metrics – Forecast & Growth Curves

5.2 Regional Revenue Footprint – Market Share Insights

5.3 Segmental Wealth Flow – Drug Type & Therapeutic Area Revenue

CHAPTER NO. 6 : TRADE & COMMERCE ANALYSIS

6.1.Import Analysis By Region

6.1.1. Global Sterile Injectables Market Import Revenue By Region

6.2.Export Analysis By Region

6.2.1. Global Sterile Injectables Market Export Revenue By Region

CHAPTER NO. 7 : COMPETITION ANALYSIS

7.1.Company Market Share Analysis

7.1.1. Global Sterile Injectables Market: Company Market Share

7.2. Global Sterile Injectables Market Company Revenue Market Share

7.3.Strategic Developments

7.3.1.Acquisitions & Mergers

7.3.2. New Product Launch

7.3.3. Regional Expansion

7.4. Competitive Dashboard

7.5. Company Assessment Metrics, 2024

CHAPTER NO. 8 : STERILE INJECTABLES MARKET – BY DRUG TYPE SEGMENT ANALYSIS

8.1.Sterile Injectables Market Overview By Drug Type Segment

8.1.1. Sterile Injectables Market Revenue Share By Drug Type

8.2. Monoclonal Antibodies

8.3. Cytokines

8.4. Insulin

8.5. Immunoglobulin

8.6. Vaccines

8.7. Peptide Hormones

8.8. Peptide Antibiotics

8.9 Blood Factors

8.10 Others

CHAPTER NO. 9 : STERILE INJECTABLES MARKET – BY THERAPEUTIC AREA SEGMENT ANALYSIS

9.1.Sterile Injectables Market Overview By Therapeutic Area Segment

9.1.1. Sterile Injectables Market Revenue Share By Therapeutic Area

9.2. Cancer

9.3. Infectious Diseases

9.4. Diabetes

9.5. Cardiovascular Diseases

9.6. Neurological Diseases

9.7. Musculoskeletal Diseases

9.8. Others

CHAPTER NO. 10 : STERILE INJECTABLES MARKET – REGIONAL ANALYSIS

10.1.Sterile Injectables Market Overview By Region Segment

10.1.1. Global Sterile Injectables Market Revenue Share By Region

10.1.2.Regions

10.1.3.Global Sterile Injectables Market Revenue By Region

10.1.4. Drug Type

10.1.5.Global Sterile Injectables Market Revenue By Drug Type

10.1.6.Therapeutic Area

10.1.7. Global Sterile Injectables Market Revenue By Therapeutic Area

CHAPTER NO. 11 : NORTH AMERICA STERILE INJECTABLES MARKET – COUNTRY ANALYSIS

11.1.North America Sterile Injectables Market Overview By Country Segment

11.1.1. North America Sterile Injectables Market Revenue Share By Region

11.2.North America

11.2.1.North America Sterile Injectables Market Revenue By Country

11.2.2.Drug Type

11.2.3. North America Sterile Injectables Market Revenue By Drug Type

11.2.4.Therapeutic Area

11.2.5. North America Sterile Injectables Market Revenue By Therapeutic Area

11.3.U.S.

11.4.Canada

11.5.Mexico

CHAPTER NO. 12 : EUROPE STERILE INJECTABLES MARKET – COUNTRY ANALYSIS

12.1. Europe Sterile Injectables Market Overview By Country Segment

12.1.1. Europe Sterile Injectables Market Revenue Share By Region

12.2.Europe

12.2.1.Europe Sterile Injectables Market Revenue By Country

12.2.2. Drug Type

12.2.3.Europe Sterile Injectables Market Revenue By Drug Type

12.2.4.Therapeutic Area

12.2.5. Europe Sterile Injectables Market Revenue By Therapeutic Area

12.3.UK

12.4.France

12.5.Germany

12.6.Italy

12.7.Spain

12.8.Russia

12.9. Rest of Europe

CHAPTER NO. 13 : ASIA PACIFIC STERILE INJECTABLES MARKET – COUNTRY ANALYSIS

13.1.Asia Pacific Sterile Injectables Market Overview By Country Segment

13.1.1. Asia Pacific Sterile Injectables Market Revenue Share By Region

13.2.Asia Pacific

13.2.1. Asia Pacific Sterile Injectables Market Revenue By Country

13.2.2.Drug Type

13.2.3.Asia Pacific Sterile Injectables Market Revenue By Drug Type

13.2.4.Therapeutic Area

13.2.5.Asia Pacific Sterile Injectables Market Revenue By Therapeutic Area

13.3.China

13.4.Japan

13.5.South Korea

13.6.India

13.7.Australia

13.8.Southeast Asia

13.9. Rest of Asia Pacific

CHAPTER NO. 14 : LATIN AMERICA STERILE INJECTABLES MARKET – COUNTRY ANALYSIS

14.1.Latin America Sterile Injectables Market Overview By Country Segment

14.1.1. Latin America Sterile Injectables Market Revenue Share By Region

14.2. Latin America

14.2.1. Latin America Sterile Injectables Market Revenue By Country

14.2.2.Drug Type

14.2.3. Latin America Sterile Injectables Market Revenue By Drug Type

14.2.4.Therapeutic Area

14.2.5. Latin America Sterile Injectables Market Revenue By Therapeutic Area

14.3.Brazil

14.4.Argentina

14.5.Rest of Latin America

CHAPTER NO. 15 : MIDDLE EAST STERILE INJECTABLES MARKET – COUNTRY ANALYSIS

15.1.Middle East Sterile Injectables Market Overview By Country Segment

15.1.1. Middle East Sterile Injectables Market Revenue Share By Region

15.2.Middle East

15.2.1. Middle East Sterile Injectables Market Revenue By Country

15.2.2.Drug Type

15.2.3.Middle East Sterile Injectables Market Revenue By Drug Type

15.2.4.Therapeutic Area

15.2.5.Middle East Sterile Injectables Market Revenue By Therapeutic Area

15.3.GCC Countries

15.4. Israel

15.5. Turkey

15.6.Rest of Middle East

CHAPTER NO. 16 : AFRICA STERILE INJECTABLES MARKET – COUNTRY ANALYSIS

16.1. Africa Sterile Injectables Market Overview By Country Segment

16.1.1.Africa Sterile Injectables Market Revenue Share By Region

16.2. Africa

16.2.1.Africa Sterile Injectables Market Revenue By Country

16.2.2.Drug Type

16.2.3.Africa Sterile Injectables Market Revenue By Drug Type

16.2.4.Therapeutic Area

16.2.5. Africa Sterile Injectables Market Revenue By Therapeutic Area

16.3. South Africa

16.4.Egypt

16.5.Rest of Africa

CHAPTER NO. 17 : COMPANY PROFILES

17.1. Amgen Limited

17.1.2. Product Portfolio

17.1.3.Financial Overview

17.1.4.Recent Developments

17.1.5.Growth Strategy

17.1.6.SWOT Analysis

17.2. AstraZeneca plc

17.3. Baxter International, Inc.

17.4. Eli Lilly and Company

17.5. Johnson & Johnson Services, Inc.

17.6. Merck & Co., Inc

17.7. Mylan N.V.

17.8. Pfizer, Inc.

17.9. Sanofi

17.10. Nichi-Iko Pharmaceutical Co.

17.11. Other Key Players

Request A Free Sample

We prioritize the confidentiality and security of your data. Our promise: your information remains private.

Ready to Transform Data into Decisions?

Request Your Sample Report and Start Your Journey of Informed Choices

Providing the strategic compass for industry titans.

Frequently Asked Questions:

What is the current market size for Global Sterile Injectables Market, and what is its projected size in 2032?

The Global Sterile Injectables Market reached USD 663.9 million in 2024 and is expected to grow to USD 1,122.2 million by 2032.

At what Compound Annual Growth Rate is the Global Sterile Injectables Market projected to grow between 2025 and 2032?

The Global Sterile Injectables Market is forecasted to expand steadily at a CAGR of 6.81% during 2025–2032, reflecting strong demand across therapeutic applications.

Which Global Sterile Injectables Market segment held the largest share in 2024?

By drug type, monoclonal antibodies held the largest share at 36% in 2024, driven by strong adoption in oncology and autoimmune disease treatments.

What are the primary factors fueling the growth of the Global Sterile Injectables Market?

Key drivers include the rising prevalence of chronic diseases, expanding biologics and biosimilars pipeline, and government support through immunization and healthcare infrastructure programs.

Who are the leading companies in the Global Sterile Injectables Market?

Leading players include Pfizer, Amgen, Sanofi, Johnson & Johnson, AstraZeneca, Eli Lilly, Merck, Baxter, and Mylan, each holding strong biologics and oncology portfolios.

Which region commanded the largest share of the Global Sterile Injectables Market in 2024?

North America dominated with a 33% share in 2024, supported by advanced healthcare infrastructure, strong biologics adoption, and rapid biosimilar uptake in the U.S.

About Author

Shweta Bisht

Healthcare & Biotech Analyst

Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.

View Profile

Related Reports

UK Pharmaceutical Water Market

The UK Pharmaceutical Water Market was valued at USD 299.29 million in 2018, increased to USD 550.93 million in 2024, and is projected to reach USD 1,087.93 million by 2032, expanding at a CAGR of 8.27% during the forecast period.

U.S. Pharmaceutical Water Market

The U.S. Pharmaceutical Water Market was valued at USD 5,673.65 million in 2018, increased to USD 11,018.40 million in 2024, and is projected to reach USD 23,471.03 million by 2032, expanding at a CAGR of 9.23% during the forecast period.

Italy Pharmaceutical Water Market

The Italy Pharmaceutical Water Market was valued at USD 460.92 million in 2018, grew to USD 817.32 million in 2024, and is projected to reach USD 1,534.50 million by 2032, expanding at a CAGR of 7.63% during the forecast period.

Germany Pharmaceutical Water Market

Germany Pharmaceutical Water Market size was valued at USD 658.32 million in 2018 to USD 1,223.46 million in 2024 and is anticipated to reach USD 2,448.13 million by 2032, at a CAGR of 8.44 % during the forecast period.

France Pharmaceutical Water Market

The France Pharmaceutical Water Market was valued at USD 728.61 million in 2018, grew to USD 1,310.01 million in 2024, and is projected to reach USD 2,505.44 million by 2032, expanding at a CAGR of 7.86% during the forecast period.

Fabry Disease Therapeutic Market

The Fabry Disease Therapeutic Market has witnessed steady growth in recent years and is expected to grow at a CAGR of 8.80% between 2024 and 2032. The market was valued at USD 1725.8 million in 2023 and is expected to reach USD 3686.8 million in 2032.

Foot And Mouth Disease Vaccines Market

The Foot and Mouth Disease (FMD) Vaccines market size was valued at USD 2.68 billion in 2024 and is projected to reach USD 4.78 billion by 2032, growing at a CAGR of 7.5% during the forecast period.

Idiopathic Pulmonary Fibrosis Treatment Market

The Idiopathic Pulmonary Fibrosis (IPF) Treatment market was valued at USD 3.25 billion in 2024 and is projected to reach USD 5.66 billion by 2032, expanding at a CAGR of 7.2% during the forecast period.

Hyperhidrosis Treatment Market

Hyperhidrosis Treatment Market size was valued USD 2.8 billion in 2024 and is anticipated to reach USD 4.4 billion by 2032, at a CAGR of 5.8% during the forecast period.

Hyperlipidemia Drugs Market

The Hyperlipidemia Drugs market was valued at USD 15.2 billion in 2024 and is projected to reach USD 24.04 billion by 2032, expanding at a CAGR of 5.9% during the forecast period.

Bone Glue Market

Bone Glue Market size was valued at USD 930.00 million in 2018, reached USD 1,108.36 million in 2024, and is anticipated to reach USD 1,886.27 million by 2032, at a CAGR of 7.01% during the forecast period.

Virtual PLC and Soft PLC in Pharmaceutical Market

Global Virtual PLC and Soft PLC in Pharmaceutical market size was valued at USD 149.2 million in 2018 and grew to USD 266.9 million in 2024. It is anticipated to reach USD 649.1 million by 2032, expanding at a CAGR of 11.90% during the forecast period.

Licence Option

Single User

$4999

Multi User

$6999

Enterprise

$12999

Report delivery within 24 to 48 hours

Let us help you

WILLIAM, North America

+1 304 308 1216

KEITH PHILLIPS, Europe

+44 7809 866 263

LEE VALLANCE, Asia Pacific

+64 22 017 0275

KIERAN JAMESON, Australia

+61 4192 46279

Request A Free Sample

What people say?

Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.

Materials Scientist
(privacy requested)

The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.

Imre Hof
Management Assistant, Bekaert

Trusted By

Request Sample